CureVac (NASDAQ:CVAC – Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $2.44, but opened at $2.51. CureVac shares last traded at $2.49, with a volume of 88,287 shares traded.
Analyst Ratings Changes
Separately, Guggenheim reiterated a “neutral” rating on shares of CureVac in a report on Friday, April 5th.
CureVac Trading Up 2.8 %
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in CVAC. Platinum Investment Management Ltd. raised its position in CureVac by 60.6% in the third quarter. Platinum Investment Management Ltd. now owns 363,280 shares of the company’s stock worth $2,481,000 after purchasing an additional 137,146 shares in the last quarter. TD Asset Management Inc raised its position in CureVac by 66.8% in the third quarter. TD Asset Management Inc now owns 209,094 shares of the company’s stock worth $1,428,000 after purchasing an additional 83,747 shares in the last quarter. Jump Financial LLC acquired a new position in CureVac in the fourth quarter worth about $346,000. Dynamic Technology Lab Private Ltd acquired a new position in CureVac in the fourth quarter worth about $160,000. Finally, Aristides Capital LLC acquired a new position in CureVac in the fourth quarter worth about $100,000. Institutional investors and hedge funds own 17.26% of the company’s stock.
About CureVac
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.
Read More
- Five stocks we like better than CureVac
- Stock Market Sectors: What Are They and How Many Are There?
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Stock Dividend Cuts Happen Are You Ready?
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.